Mesothelin-specific immune responses may also aid to identify patients i) at increased risk for tumor progression ii) who may benefit from a more frequent followup and alternate treatment strategies, including immunotherapeutic strategies with the aim to expand anti-cancer T-cells. The gene discussed is MSLN; the disease is cancer.